A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

Posted by rob on July 31, 2011 under Uncategorized | Comments are off for this article

Conclusions  Bosutinib 200–600 mg with food was safe and well tolerated. Under fed conditions, bosutinib exposures were linear and dose
proportional, and C
max increased by ~1.5-fold. The t
1/2 supported a once-daily dosing regimen.

Content Type Journal ArticlePages 1-7DOI 10.1007/s00280-011-1688-7Authors
Richat Abbas, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USABruce A. Hug, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USACathie Leister, Department of Clinical Pharmacology, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USAMyriam El Gaaloul, Department of Clinical Pharmacology, Pfizer Global Research and Development, Paris, FranceStephan Chalon, Department of …
More